Rexahn Pharmaceuticals has announced the appointment of Douglas J. Swirsky as its president and chief financial officer. 

Mr. Swirsky was most recently president, chief executive officer, and a director of GenVec, Inc., a publicly-traded biotechnology company. He is on the board of directors of Fibrocell Science, Inc., Cellectar Biosciences, Inc., and Pernix Therapeutics Holdings, Inc.  

“Doug’s extensive leadership, corporate finance and strategy experience make him a strong addition to the Rexahn team,” said Dr. Peter Suzdak, chief executive officer for Rexahn Pharmaceuticals.  “We look forward to Doug’s contributions as we progress our clinical programs through proof of concept studies to later stage clinical development.”  

Mr. Swirsky replaces Dr. Tae Heum “Ted” Jeong, sr. vice president of Finance, chief financial officer, and secretary, who informed the Company of his resignation in December to pursue another opportunity.